Alere (ALR) : 3 days before expiry, shorts in Alere (ALR) have reduced from 3,193,722 on Jul 29, 2016, to 2,949,672 on August 15, 2016. On an average, 1,065,478 shares are traded on the exchange. The outstanding bearish positions are equal to 3.4% of the float. Short sellers have covered -244,050 shares, a reduction of -7.6%, which underlines that they dont expect the stock to fall further from the current levels. The short interest information was released on Wednesday Aug 24th after the market close.
Alere (NYSE:ALR): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $40.55 and $40.18 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $40.91. The buying momentum continued till the end and the stock did not give up its gains. It closed at $40.62, notching a gain of 0.27% for the day. The total traded volume was 492,388 . The stock had closed at $40.51 on the previous day.
In a related news,The officer (VP, Chief Accounting Officer) of Alere Inc., Flakne Carla sold 10,000 shares at $42.44 on January 16, 2015. The Insider selling transaction had a total value worth of $424,400. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Alere Inc. is a provider of health information through diagnostic tests. The Company operates through professional diagnostics, patient self-testing, consumer diagnostics and, corporate and other segments. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus. The patient-self testing segment provides services designed to provide physicians with actionable data that allow them to make decisions in real time, deliver care, and put the individuals they treat on a pathway to better health. The consumer diagnostics segment consists primarily of manufacturing operations related to its role as the exclusive manufacturer of products for SPD Swiss Precision Diagnostics (SPD), its 50/50 joint venture with The Procter & Gamble Company (P&G).